Marker Therapeutics, Inc. (NASDAQ:MRKR) headquartered in Houston, will host a conference call for the investment community to discuss the 3Q20 financial results on 9th November 2020 at 5:00 PM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.markertherapeutics.com
Earnings Expectation
Marker Therapeutics, Inc. is reporting third quarter financial results on Monday 9th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, MRKR is expected to report 3Q20 loss of $ 0.14 per share. For the full year, analysts anticipate top line of $ 0.48 million, while looking forward to loss of $ 0.56 per share bottom line.
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company is developing TPIV100/110, which is in Phase II clinical trial to treat human epidermal growth factor receptor 2 breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers.
